1. FRI0173 Gastrointestinal perforations with certolizumab PEGOL. (23rd January 2014) Authors: Fleischmann, R.; Rubbert-Roth, A.; Combe, B.; VanLunen, B.; Andrews, P.; de Longueville, M. Journal: Annals of the rheumatic diseases Issue: Volume 71(2012)Supplement 3 Page Start: 370 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FRI0186 Long-term safety and efficacy of 4-weekly certolizumab pegol monotherapy and combination therapy in rheumatoid arthritis: 5-year results from an open-label extension study. (23rd January 2014) Authors: Fleischmann, R.; van Vollenhoven, R.; Vencovsky, J.; Alten, R.; Davies, O.; Stach, C.; de Longueville, M.; VanLunen, B.; Choy, E. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A435 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. OP0227 A Randomized Double-Blind Treatment Strategy Study Evaluating Continuation or Reduced-Frequency Dosing of Certolizumab Pegol versus Withdrawal To Maintain Low Disease Activity in Early RA Patients (C-Early Period 2). (15th July 2016) Authors: Emery, P.; Bingham, C.; Burmester, G.-R.; Bykerk, V.P.; Furst, D.; Mariette, X.; van der Heijde, D.; van Vollenhoven, R.; VanLunen, B.; Ecoffet, C.; Cioffi, C.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 143 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. SAT0164 The First Study of Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients Led to Sustained Clinical Response and Inhibition of Radiographic Progression at 52 Weeks: The C-Early Randomized, Double-Blind, Controlled Phase 3 Study. (9th June 2015) Authors: Emery, P.; Bingham, C.O.; Burmester, G.-R.; Bykerk, V.P.; Furst, D.E.; Mariette, X.; van der Heijde, D.; Tatla, D.; Arendt, C.; Mountian, I.; VanLunen, B.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 712 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. SAT0165 Improvements in Patient-Reported Outcomes and Workplace and Household Productivity Following 52 Weeks of Treatment with Certolizumab Pegol in Combination with Methotrexate in Dmard-Naïve Early Rheumatoid Arthritis Patients: Results from the C-Early Randomized, Double-Blind, Controlled Phase 3 Study. (9th June 2015) Authors: Emery, P.; Bingham, C.O.; Burmester, G.-R.; Bykerk, V.P.; Furst, D.E.; Mariette, X.; Purcaru, O.; Coteur, G.; VanLunen, B.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 74(2015)Supplement 2 Page Start: 712 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. SAT0202 Comparison of the bioavailability of a single dose of certolizumab pegol injected by pre-filled syringe or by electro-mechanical auto-injection e-device: a phase 1, open-label, randomised, parallel group, single-centre bioequivalence study. (12th June 2018) Authors: Oliver, R.; VanLunen, B.; Mountian, I.; Brown, E.; Tatla, D. Journal: Annals of the rheumatic diseases Issue: Volume 77(2018)Supplement 2 Page Start: 961 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. THU0128 Maintenance of Improvements in Workplace and Household Productivity and Physical Function at 2 Years in Early RA Patients with Severe Progressive Disease Who Achieved Sustained Low Disease Activity Following 1 Year of Initial Therapy, with Two Dosing Frequencies of Certolizumab Pegol. (15th July 2016) Authors: Bingham, C.; Emery, P.; Weinblatt, M.; Burmester, G.-R.; Furst, D.E.; Mariette, X.; van Vollenhoven, R.; VanLunen, B.; Purcaru, O.; Bykerk, V.P. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. THU0163 Early Response as A Predictor of Long-Term Clinical Response in DMARD-Naïve Patients with Severe, Active and Progressive RA Treated with Certolizumab Pegol plus Optimized MTX versus Optimized MTX Alone. (15th July 2016) Authors: Mariette, X.; Bingham, C.; Burmester, G.-R.; Bykerk, V.P.; Emery, P.; Furst, D.; van der Heijde, D.; van Vollenhoven, R.; VanLunen, B.; Arendt, C.; Weinblatt, M. Journal: Annals of the rheumatic diseases Issue: Volume 75(2016)Supplement 2 Page Start: 242 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. THU0192 5-Year Results from the Rapid 1 Trial and Open-Label Extension: Long-Term Safety and Efficacy of Certolizumab Pegol in Combination with Methotrexate in the Treatment of Rheumatoid Arthritis. (23rd January 2014) Authors: Keystone, E.; Landewé, R.; van Vollenhoven, R.; Combe, B.; Strand, V.; Mease, P. J.; Shaughnessy, L.; VanLunen, B.; van der Heijde, D. Journal: Annals of the rheumatic diseases Issue: Volume 72:Supplement 3(2013) Page Start: A228 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗